Major Partner Validated IP · Rare Broad-Field Patents · Level 1 Science · Direct path to market

E² — Solving Tissue Ablation

Successor technology to IRE — from the same group that invented, patented, and commercialized IRE and Cryoablation. Prostate-optimized, designed for multi-organ expansion.

🏥 Major medtech partner secured 📄 Several patents issued & pending 🔬 15+ peer-reviewed publications 🇺🇸 FDA pathway active
Explore Technology →
<90sAblation Time
5+ cmAblation Field
15+Publications
E² QuickPulse Generator
The Challenge

Focal Therapy Isn't the Standard — Because It Can't Reach Everyone

Despite clear clinical benefits, non-thermal focal ablation remains niche. Systemic barriers prevent widespread adoption.

⏱ Time-Intensive

Long OR times, anesthesia requirements, and complex setup make focal therapy difficult to integrate into daily clinical routines — limiting patient throughput.

⚠️ Strict Probe Placement Limitations

Current systems require parallel electrode placement with short distances, short exposure length and strict geometric constraints, increasing procedural complexity and cost.

🔥 Thermally Constrained

Thermal methods risk damaging critical structures — vessels, nerves, urethra — excluding a large patient population from focal therapy.

💰 Capital Intensive

Multi-electrode disposable costs and cumbersome workflows create vendor friction and operational burden — discouraging adoption.

📐 Procedurally Complex

Complex workflows requiring specialized training limit the number of physicians who can offer focal therapy.

The Solution

High-Impact Selective Ablation, Built for the Real World

E² QuickPulse harnesses the synergy of electroporation and electrolysis — enabling faster, safer, and more scalable tissue ablation near critical anatomy.

01

Built for Clinical Scale

Short procedure times, low capital, streamlined setup.

  • Sub-90-second ablation cycles
  • Flexible electrode configurations
  • No strict geometric constraints
02

Safe Near Critical Structures

Designed for precise ablation near blood vessels, nerves, urethra, and rectum.

  • Non-thermal mechanism
  • Clean ablation margins
  • ECM preservation
03

300–1000% More Volume vs IRE

Dramatically larger ablation volumes with lower energy. Small or large volumes, no strict geometric constraints.

  • 5+ cm ablation field
  • Scalable via electrode geometry
  • Favorable safety profile

Procedural Workflow: IRE vs E² QuickPulse

Conventional IRE
🏥 General anesthesia required
📐 Multiple parallel electrode placement
⏱ Up to 30 min treatment time
💰 High disposable costs
→
E² QuickPulse (Design Target)
💉 Local / sedation possible
🎯 Flexible electrode configurations
🚀 <90 seconds ablation
📉 Lower disposable costs

Design targets. Individual results may vary.

The Science

Rewriting the Rules of Ablation with E²

E² is based on the synergistic combination of electroporation and electrolysis — two well-understood mechanisms that together achieve what neither can alone.

E² Mechanism
1

Electrolysis

Generates localized chemical species and pH shifts. Alone, effective but slow — often taking hours.

2

Electroporation

Reversible EP pulses temporarily increase membrane permeability. Alone, requires high voltage and limits lesion size.

E²

The E² Synergy

Electrolysis products enter cells through electroporated membranes — fast, large-volume ablation with lower energy, clean margins, and favorable safety.

Understanding the E² Advantage

Limit of IRE

1. The Limit of IRE

IRE is constrained by the physics of electric fields. Only the very center achieves the threshold for cell death. The rest is sub-lethal.

Reversible Zone

2. The Reversible Halo

A massive "halo" of reversibly electroporated tissue surrounds every RE application. Current technologies ignore this. E² targets it.

Geometric Limitations

3. Complexity & Failure Modes

To cover a tumor with small IRE zones, you need many needles and perfect alignment. One millimeter off, and cancer cells survive.

Synergistic Mechanism

4. Synergistic Mechanism

E² introduces a chemical variable (pH/electrolysis) into the electrical equation. The reversible pores act as gateways for these agents to kill the cell from within.

Superior Outcome

5. Superior Clinical Outcome

The result: A large, continuous ablation zone created in seconds. Safer than thermal inputs, faster than electrolysis alone.

Patented & Secured

6. Intellectual Property

This specific combination of electrolytic production and electroporation delivery is covered by our foundational issued patents.

How E² Compares

Current ablation technologies vs E² QuickPulse design targets

Technology Precision Ablation Size Speed Immunology Ease of Use
IRE Excellent, Selective 1–3 cm Up to 30 min Excellent (IP limited) Complex
Radio / Microwave Moderate, Non-selective 1–5 cm Up to 10 min Little Simple
Cryoablation Excellent, Non-selective 2–3 cm Up to 30 min Good Complex
E² QuickPulse Excellent, Selective 5+ cm <90 seconds Excellent & Optimizable Simple

Source: InterScience internal benchmarking. E² figures are design targets. IRE, Cryoablation, and E² — all invented by this team.

Scientifically Established from the Ground Up

15+ peer-reviewed publications by the Berkeley / InterScience group

2015

Phillips M, et al. "Modulating electrolytic tissue ablation with reversible electroporation pulses." Technology 3(1):1-19

First demonstration that reversible EP pulses modulate electrolytic ablation — foundation of E².
2015

Phillips M, et al. "Combining Electrolysis and Electroporation for Tissue Ablation." Technol Cancer Res Treat 14(4)

Histological proof in rat liver: well-demarcated ablation with ECM preservation.
2016

Phillips M, et al. "Tissue Ablation by Synergistic Combination…" Ann Biomed Eng 44(10)

Single-pulse E² — electrolysis and electroporation from one exponential-decay pulse.
2016

Rubinsky B, Gunther E, et al. "Minimally Invasive, Non-Thermal Tissue Ablation…" J Transl Med Res 21(4)

Pig liver model confirms E² in clinically relevant large-animal setting.
2016

Stehling MK, Guenther E, et al. "Synergistic Combination…" PLoS ONE 11(2):e0148317

Large-animal validation with histological evidence.
2017

Klein N, Guenther E, et al. "Single exponential decay waveform…" PeerJ 5:e3190

EEW/EDW waveform — combined E² from a single waveform.
2019

Klein N, et al. "…for ablation of large tissue volumes." PLoS ONE 14(8):e0221393

Multi-electrode arrays extend E² to large tissue volumes.
2020

Guenther E, et al. "Toward clinical real time tissue ablation…" PeerJ 8:e7985

Single-pulse E² in sub-second timeframe proves clinical feasibility.
2020

Klein N, et al. "In vitro study on mechanisms of action…" Bioelectrochemistry 133:107482

Identifies necrotic and pyroptotic cell-death pathways in E².
2023

Salameh ZS, et al. "Harnessing Electrochemical Effects…" Ann Biomed Eng 52:48-56

E² electrochemical products may enhance anti-tumor immune response.
# Year Citation Type DOI
1 2015 Phillips M, et al. "Modulating electrolytic tissue ablation…" Technology 3(1):1-19 Our Original DOI
2 2015 Phillips M, et al. "Combining Electrolysis and Electroporation…" TCRT 14(4):395-410 Our Original DOI
3 2016 Phillips M, et al. "Tissue Ablation by Synergistic Combination…" Ann Biomed Eng 44(10) Our Original DOI
4 2016 Rubinsky B, Gunther E, et al. "Minimally Invasive, Non-Thermal…" JTMR 21(4) Our Original DOI
5 2016 Stehling MK, Guenther E, et al. "Synergistic Combination…" PLoS ONE 11(2) Our Original DOI
6 2017 Klein N, Guenther E, et al. "Single exponential decay waveform…" PeerJ 5:e3190 Our Original DOI
7 2018 González MM, et al. "Tissue Damage, Temperature, pH…" Front Oncol 8:101 Original DOI
8 2018 Zhang Y, et al. "Molecular and histological study…" BBRC 500:665-670 Our Original DOI
9 2019 Klein N, et al. "…different electrode arrays for large volumes." PLoS ONE 14(8) Our Original DOI
10 2019 Lv Y, et al. "Conceivable Mechanism…" Ann Biomed Eng 47(10) Original DOI
11 2020 Guenther E, et al. "Toward clinical real time…" PeerJ 8:e7985 Our Original DOI
12 2020 Klein N, et al. "In vitro study on mechanisms…" Bioelectrochemistry 133:107482 Our Original DOI
13 2021 Klein N. PhD Thesis — Mechanisms of electrolytic electroporation Our Thesis —
14 2023 Salameh ZS, et al. "Harnessing Electrochemical Effects…" Ann Biomed Eng 52:48-56 Original DOI
15 2024 Šmerc R, et al. "Validated Numerical Model of pH Changes…" Electrochim Acta Original DOI
Patents
P1 2015 "Combining EP and Electrolysis for Tissue Ablation" Patent WO WO2015073885A1
P2 2020 "Modulated Exponential Decay E2" Patent WO WO2020051241
P3 2024 "Methods and Systems for Modulated E2" Patent US Issued US12127779B2
P4 2024 "E2 Waveform Platform" Patent WO WO2024081749A2
P5 2025 "Immunomodulation Optimization" Patent US App US20250195128
Market Opportunity

A Platform That Scales — For Everyone at the Table

E² solves both a technical and an adoption problem. Fast setup, fundable procedures, recurring margins.

BPH: A Massive, Growing U.S. Market

>100MGlobal BPH treatment market
~14MU.S. men diagnosed with BPH
~2.5MProgressing beyond medication annually
~600KAnnual surgical / MIS intervention
>1ME² target opportunity in U.S. alone

Global Expansion

United States
$4.5B+
Prostate therapy TAM
European Union
$3.2B+
Growing focal therapy adoption
China & APAC
Sub-License
E-Cryo sub-licensed to China partner
🏥

Patients

Access to hard-to-reach cases. Less invasive, faster recovery.

⚕️

Clinics

Lower OR time, high margins, CPT-funded (2026).

📈

InterScience

Recurring disposable revenue. Capital-light, scalable.

Intellectual Property

We Control the Field

Our IP mirrors the proven blocking approach that kept IRE competitors at bay for over a decade.

🛡 Broad Foundational Patent

Issued field patent covering all combinations of electrolysis with electroporation. Broader and stronger than the original IRE patent.

⚡ Implementation Patents

Claims cover method, device, and waveform. Enables cross-over use of IRE and thermal modalities in a single apparatus.

🧬 Future-Proof Coverage

Vast coverage into abscopal-optimized ablation and immunomodulatory therapies. Patent pending.

✓ Validated & Licensed

Patent strength validated through due diligence by leading medtech companies. Already licensed — generating revenue.

"We don't just protect a product — we control the field."
Development Roadmap

$5M to FDA Clearance

Four-phase plan from prototype to 510(k). Previously advanced a device to near-final IEC 60601 testing under ISO 13485.

Nov 2025 — Mar 2026

Phase 1: Planning & De-Risk

Secure funding. Requirements and risk mitigation.

$1.0M
Mar — Oct 2026

Phase 2: Alpha Prototype

Functional alpha. Electrode and waveform specs.

$1.7M
Oct 2026 — Feb 2027

Phase 3: DV Prototype

Design verification. Formal V&V preparation.

$1.6M
Feb — Jul 2027

Phase 4: V&V & Certification

Testing complete, 510(k) submitted.

$700K
Target: Nov 2027

FDA Clearance

Begin U.S. commercialization.

Seed+ Round: $5M SAFE

Swiss-Law Equivalent
$20MValuation Cap
20%Discount
AutoSeries A Convert
$100-400MComparable Exits

We seek active partners — network access to clinical trial sites, early adopters, and strategic co-investors. Major global medtech partner already secured. Several major market-facing announcements expected. The main E² field remains available at current valuations.

Leadership

From the Inventors of IRE & Cryoablation

~8-year-old UC Berkeley spin-off. IRE, Cryoablation, and E² — all invented by members of this team.

Boris Rubinsky

Prof. Boris Rubinsky

Co-Founder & Inventor
  • UC Berkeley Professor
  • 300+ papers, ~40 US patents
  • Inventor of IRE and Cryoablation
  • Over 10 SNP500 companies use or have bought his inventions
Enric Günther

Enric Günther

CEO & Co-Founder
  • Physicist & computer scientist
  • UC Berkeley research scholar
  • 10+ publications in EP
  • Led E² from invention through research to development to first major deal
Angelo Arnold

Angelo Arnold

COO
  • Business development
  • Former financial consultant
  • Financial modelling
  • Startup operations
Michael Stehling

Prof. Michael Stehling

Founder & CMO
  • Physicist
  • Professor of Radiology
  • Nobel laureate's assistant (MRI)
  • A leading IRE prostate treatment expert
  • Serial entrepreneur
Richard Stark

Richard Stark

Consultant
  • CEO of Innoblative (SIRA®)
  • Co-founded MedTech Angels
  • Global medtech advisor
  • Fundraising & regulation
Execution is the focus. We've done this before. Major partnership with one of the largest and most innovative medical device company in the world for a special sub-license of E² has been signed. ISO 13485 and IEC 60601 ready prototype have been built. China partnership for a sub-license of a special form of E² (E-Cryo) extends our reach into China. We now set out we meant to do with E² from the beginning: Set a new standard for ablation in the whole world — starting with prostate.

Join Us in Changing How Cancer Is Treated

The window for early-stage partnership is open.

📊 Investors

Request our investor deck, financial model, and diligence materials.

🤝 Strategic Partners

Explore clinical collaboration, licensing, or technology partnerships.

👨‍⚕️ Interested Surgeons

Join our early clinical access program and trial E² in your practice.